CBD Inhibited a Brain Enzyme Linked to Neurodegeneration at Nanomolar Concentrations in Lab Tests

Computational screening of 7 phytocannabinoids and 4 terpenes identified CBD as a potential PDE9 ligand with a calculated binding energy of -9.1 kcal/mol and stable molecular dynamics interaction. In vitro PDE9 inhibition assay confirmed CBD inhibits the enzyme in the nanomolar range.

Combined ligand-based and structure-based virtual screening (docking and molecular dynamics simulations) followed by in vitro PDE9 enzymatic inhibition assay. Screened 7 phytocannabinoids and 4 terpenes.

PDE9 inhibitors are being studied as potential treatments for Alzheimer disease and other neurodegenerative conditions. If CBD acts partly through PDE9 inhibition, this could explain some of its reported neuroprotective effects and open a new avenue for drug development.

CBD has shown neuroprotective effects in various studies, but the mechanisms remain unclear. Identifying PDE9 as a specific molecular target adds a concrete mechanism to what has been a vague body of evidence about CBD and brain health.

In vitro enzymatic assay does not confirm in vivo relevance. Nanomolar potency in a cell-free system may not translate to effective brain concentrations. CBD has many proposed molecular targets, and PDE9 may be one of many. No animal or human data yet.